Ketoprofen Cataplasms authorized by National Healthcare Security Administration, on NRDL

Release time:

2023-12-13 16:34

Source:

Abstract

At the end of 2023, National Healthcare Security Administration announced the results of the adjustment of NRDL (The National Reimbursement Drug List, NRDL was introduced in 2000 to support medical healthcare and providing patients with basic medical treatments.), there are 126 drugs newly added. Jiudian Pharmaceutical's exclusive dosage form Ketoprofen Cataplasms is one of them. The new NRDL will be officially implemented on January 1, 2024.

At this point, Jiudian have 60 varieties and 74 specifications on NRDL.

Ketoprofen Cataplasms was on the Market at the end of Feb, 2023, and on NRDL after 10 months. It reflects the recognition and attention of all sectors of society for external use of non-steroidal anti-inflammatory drugs.

This help Jiudian Pharmaceutical’s Ketoprofen Cataplasms market grow rapidly.

Hunan Jiudian Pharmaceutical have Market Authorization of Methyl Salicylate and Sodium Sulfate APIs from NMPA

Jiudian Hongyang Pharmaceutical have Market Authorization of Ketoprofen API from NMPA

Hunan Jiudian Pharmaceutical have Market Authorization of Methyl Salicylate and Sodium Sulfate APIs from NMPA

Jiudian Hongyang Pharmaceutical have Market Authorization of Ketoprofen API from NMPA

Time is measured in two ways: one by the stopwatch, tracking precision to 0.01 seconds; the other by the growth rings, engraving the dawns and dusks of 365 days. On October 10, 2017, a resounding bell echoed through the venue, as the stock code "300705" lit up the large screen—announcing our first commitment to the times. Today, if we "rewind" that bell, we can still hear the pulse of that moment: it is the heartbeat of Jiudian, and also the heartbeat of every patient, customer, shareholder, and employee.

10-10

2025

Jiudian Pharmaceutical Marks 8th Listing Anniversary United for Shared Prosperity, Embarking on a New Journey

United in Purpose, Sailing Toward Success; Quality as Priority, Achieving Excellence

On September 28th, the On-site QA Office of Jiudian Hongyang successfully held a team-building activity themed "United in Purpose, Sailing Toward Success; Quality as Priority, Achieving Excellence". Organized under the overall coordination of supervisor of the On-site QA Office and team leader, this activity aimed to strengthen the entire team's awareness of quality responsibility by conducting in-depth analysis of recent typical customer complaint cases, identify quality risk points in various production workshops, and enhance team collaboration capabilities. Its ultimate goal was to realize the objective of "promoting quality through unity and achieving excellence through win-win cooperation".

09-30

2025

United in Purpose, Sailing Toward Success; Quality as Priority, Achieving Excellence

Registration Announcement of Jiudian Hongyang's Pharmaceutical Excipient: Polyacrylic Acid Solution

Recently, a piece of exciting news has emerged: the polyacrylic acid solution (Registration No.: F20250000498) developed by Jiudian Hongyang as a pharmaceutical excipient has successfully obtained the registration certificate from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.

09-25

2025

Registration Announcement of Jiudian Hongyang's Pharmaceutical Excipient: Polyacrylic Acid Solution

Hunan Jiudian

Bldg A1, Wukuang Lugu Science and Technology Industry Park, No.28 Lutian Road, Hi-tech development zone, Changsha, Hunan, China TEL. 0086-731-88220222

1

Business license